Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Corcept Therapeutics (CORT) Stock Price & Analysis
609 Followers
CORT Stock Chart & Stats
Day’s Range$22.62 - $23.44
52-Week Range― - ―
Previous Close$23
Volume609.35K
Average Volume (3M)N/A
Market Cap
$2.34B
Enterprise Value$2.01B
Total Cash (Recent Filing)$368.22M
Total Debt (Recent Filing)$151.00K
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding103,517,388
10 Day Avg. Volume751,907
30 Day Avg. Volume822,724
Standard Deviation0.14
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.78
Price to Sales (P/S)17.58
Price to Cash Flow (P/CF)102.80
P/FCF Ratio102.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.17
Enterprise Value/Gross Profit4.23
Enterprise Value/Ebitda17.09
Forecast
1Y Price Target
$33.50Price Target Upside48.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Corcept Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsCorcept's upcoming Phase III relacorilant read-out in Cushing's suggests a potential buying opportunity as positive results could significantly enhance the stock's value.
Financial PerformanceThe company's robust cash position of $425M is a testament to its financial health, potentially reassuring investors of its capability to fund operations and invest in future growth.
Sales GrowthKorlym sales have shown a 10% growth compared to the previous quarter, indicating a strong and growing demand for the company's product.
Bears Say
Intellectual PropertyCorcept's appeal faces a higher bar for success, raising concerns about the company's ability to protect its Cushing's syndrome franchise from generic threats.
Legal IssuesA disappointing court ruling for Corcept regarding Korlym litigation with Teva allows for earlier generic competition, potentially impacting Corcept's market share in Cushing's syndrome treatments.
Market CompetitionWith Teva's potential generic entry before the anticipated 2037 timeline, Corcept's revenue projections for Korlym could be significantly undermined.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Feb 15, 2024. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.258 by $0.022.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is $0.22.
How many shares outstanding does Corcept Therapeutics Inc. have?
Currently, no data Available
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.28 in its last earnings report, beating expectations of $0.258. Following the earnings report the stock price went down -7.155%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 11M.
---
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.50 (48.03% Upside)
$33.50 (48.03% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 10.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 7.3%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.40%
12-Months-Change
Fundamentals
Return on Equity
20.92%
Trailing 12-Months
Asset Growth
6.53%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
CORT Earnings Call
Q4 2024
0:00 / 0:00
---
CORT Stock 12 Months Forecast
Average Price Target
$33.50
▲(48.03% Upside)
Technical Analysis
Best Analysts Covering CORT
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+6.97%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +6.97% per trade.
---